Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating CG5503 Prolonged Release for moderate-to-severe knee osteoarthritis pain has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Knee Osteoarthritis
• Pain

Drugs mentioned

• CG5503 Prolonged Release

Snippet

Sponsor: Grünenthal GmbH | Conditions: Pain, Knee Osteoarthritis | Phase 3 | Status: COMPLETED | Results posted: 2011-01-11